These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
4. Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer. Li S; Zhang C; Pang G; Wang P Front Immunol; 2020; 11():603157. PubMed ID: 33178229 [TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176 [TBL] [Abstract][Full Text] [Related]
7. Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future Directions. Bhalla S; Doroshow DB; Hirsch FR Cancer J; 2020; 26(6):507-516. PubMed ID: 33298722 [TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
9. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Zhou F; Qiao M; Zhou C Cell Mol Immunol; 2021 Feb; 18(2):279-293. PubMed ID: 33177696 [TBL] [Abstract][Full Text] [Related]
10. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603 [TBL] [Abstract][Full Text] [Related]
11. Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1. Cabezón-Gutiérrez L; Custodio-Cabello S; Palka-Kotlowska M; Alonso-Viteri S; Khosravi-Shahi P Clin Lung Cancer; 2021 Sep; 22(5):381-389. PubMed ID: 33875382 [TBL] [Abstract][Full Text] [Related]
12. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728 [TBL] [Abstract][Full Text] [Related]
13. [Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in Non-small Cell Lung Cancer]. Wang P; Tang C; Liang J Zhongguo Fei Ai Za Zhi; 2021 Jul; 24(7):503-512. PubMed ID: 34187157 [TBL] [Abstract][Full Text] [Related]
14. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698 [TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer. Hallqvist A; Rohlin A; Raghavan S Scand J Immunol; 2020 Dec; 92(6):e12980. PubMed ID: 33015859 [TBL] [Abstract][Full Text] [Related]
16. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors. Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J Front Immunol; 2020; 11():1173. PubMed ID: 32587591 [No Abstract] [Full Text] [Related]
17. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898 [TBL] [Abstract][Full Text] [Related]
18. Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. Liu C; Wang S; Zheng S; Xu F; Cao Z; Feng X; Wang Y; Xue Q; Sun N; He J Front Immunol; 2021; 12():782106. PubMed ID: 34868057 [TBL] [Abstract][Full Text] [Related]
19. A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. Jiang Z; Zhou Y; Huang J Front Immunol; 2021; 12():813331. PubMed ID: 35003141 [TBL] [Abstract][Full Text] [Related]
20. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer. de Miguel-Perez D; Russo A; Gunasekaran M; Buemi F; Hester L; Fan X; Carter-Cooper BA; Lapidus RG; Peleg A; Arroyo-Hernández M; Cardona AF; Naing A; Hirsch FR; Mack PC; Kaushal S; Serrano MJ; Adamo V; Arrieta O; Rolfo C Cancer; 2023 Feb; 129(4):521-530. PubMed ID: 36484171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]